Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Core Insights - Biohaven Ltd. will host a conference call on September 23, 2024, to discuss topline data from Study BHV4157-206-RWE, which assesses the effectiveness of troriluzole in Spinocerebellar Ataxia [1][2] Group 1: About Troriluzole - Troriluzole is a new chemical entity and third-generation prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body [3] - The primary mode of action of troriluzole is to reduce synaptic levels of glutamate by increasing its uptake from the synapse [3] - Troriluzole has potential applications in various diseases associated with excessive glutamate [3] Group 2: About Biohaven - Biohaven is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in key therapeutic areas such as immunology, neuroscience, and oncology [4] - The company is advancing an innovative portfolio of therapeutics, leveraging proven drug development experience and proprietary drug development platforms [4] - Biohaven's clinical and preclinical programs include treatments for epilepsy, mood disorders, immunological diseases, migraine, neuropathic pain, neuroinflammatory disorders, and neuromuscular diseases [4]